Windtree Therapeutics, a Nasdaq-listed biotech firm, announced its intention to purchase up to $700 million worth of BNB, the fifth-largest cryptocurrency, following the asset's recent all-time high price of $808. The company is raising $520 million to fund these BNB purchases, with plans to allocate previously announced funds of $200 million towards the acquisition. Windtree will secure financing through a $500 million equity line of credit and another $20 million stock purchase agreement with Build and Build Corp. CEO Jed Latkin emphasized the importance of this strategy pending stockholder approval. The firm's stock price fell by 5% following the announcement, but it has experienced a substantial increase of 162% over the past month. Windtree joins a growing list of publicly traded companies, like Nano Labs and Classover, increasingly investing in digital assets to boost their stock value, expanding beyond Bitcoin to include other cryptocurrencies like BNB and Solana.

Source đź”—